Open Access

C‑Mannosyl tryptophan increases in the plasma of patients with ovarian cancer

  • Authors:
    • Naoyuki Iwahashi
    • Yoko Inai
    • Shiho Minakata
    • Sho Sakurai
    • Shino Manabe
    • Yukishige Ito
    • Kazuhiko Ino
    • Yoshito Ihara
  • View Affiliations

  • Published online on: November 28, 2019     https://doi.org/10.3892/ol.2019.11161
  • Pages: 908-916
  • Copyright: © Iwahashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer survival is poor, in part, because there are no specific biomarkers for early diagnosis. C‑Mannosyl tryptophan (CMW) is a structurally unique glycosylated amino acid recently identified as a novel biomarker of renal dysfunction. The present study investigated whether blood CMW is altered in patients with ovarian cancer and whether differences in blood CMW can distinguish benign from malignant ovarian tumors. Plasma samples were obtained from 49 patients with malignant, borderline or benign ovarian tumors as well as from seven age‑matched healthy women. CMW was identified and quantified in these samples using ultra‑performance liquid chromatography with fluorometry. Plasma CMW was significantly higher in the malignant tumor group than in the borderline and benign tumor groups, and higher in the combined tumor group (malignant, borderline or benign) compared with healthy controls. Receiver operating characteristic curve analysis of plasma CMW distinguished malignant tumors from borderline/benign tumors [area under the curve (AUC)=0.905]. Discrimination performance was greater than that of cancer antigen (CA) 125 (AUC=0.835), and CMW + CA125 combined achieved even greater discrimination (AUC=0.913, 81.8% sensitivity, 87.5% specificity, 93.1% positive predictive value and 70.0% negative predictive value). Plasma CMW differentiates malignant ovarian cancer from borderline or benign ovarian tumors with high accuracy, and performance is further improved by combined CMW and CA125 measurement.
View Figures
View References

Related Articles

Journal Cover

January 2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Iwahashi, N., Inai, Y., Minakata, S., Sakurai, S., Manabe, S., Ito, Y. ... Ihara, Y. (2020). C‑Mannosyl tryptophan increases in the plasma of patients with ovarian cancer. Oncology Letters, 19, 908-916. https://doi.org/10.3892/ol.2019.11161
MLA
Iwahashi, N., Inai, Y., Minakata, S., Sakurai, S., Manabe, S., Ito, Y., Ino, K., Ihara, Y."C‑Mannosyl tryptophan increases in the plasma of patients with ovarian cancer". Oncology Letters 19.1 (2020): 908-916.
Chicago
Iwahashi, N., Inai, Y., Minakata, S., Sakurai, S., Manabe, S., Ito, Y., Ino, K., Ihara, Y."C‑Mannosyl tryptophan increases in the plasma of patients with ovarian cancer". Oncology Letters 19, no. 1 (2020): 908-916. https://doi.org/10.3892/ol.2019.11161